First Human Dosed in Phase 1 Study of PRX002 for Treatment of Parkinson's Disease
08 avr. 2014 16h05 HE
|
Prothena Corporation plc
Entering clinic triggers $15 million milestone payment from Roche
DUBLIN, Ireland, April 8, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology...
Prothena Announces Clinical Data to be Presented at the International Symposium on Amyloidosis
18 mars 2014 16h05 HE
|
Prothena Corporation plc
DUBLIN, March 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Research and Development Update
06 mars 2014 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, March 6, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Announces Appointment of Chief Business Officer
03 mars 2014 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, March 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena to Report Fourth Quarter and Full Year 2013 Financial Results and Host Webcast and Conference Call on March 6
18 févr. 2014 16h05 HE
|
Prothena Corporation plc
Prothena to participate in February investor healthcare conferences, February 24-25
DUBLIN, Ireland, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage...
Prothena Announces Closing of Underwritten Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Ordinary Shares From Perrigo
03 févr. 2014 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Announces Pricing of Secondary Offering of Ordinary Shares by Perrigo
29 janv. 2014 08h00 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Announces Proposed Secondary Offering of Ordinary Shares by Perrigo
27 janv. 2014 16h14 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena to Receive $30 Million Upfront Payment from Roche Triggered by the Expiration of Hart-Scott-Rodino Waiting Period
23 janv. 2014 08h00 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena to be Added to NASDAQ Biotechnology Index and NASDAQ Global Select Market
30 déc. 2013 08h00 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Dec. 30, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...